Clinical trial / 2016
Oral telomerase activator TA-65 significantly improved macular function over 1 year in patients with early age-related macular degeneration.
In a 1-year, double-blind, placebo-controlled study, 38 patients with early macular degeneration were randomly assigned to receive oral TA-65 or placebo. Macular function showed significant improvement in the TA-65 arm compared to placebo, manifest at 6 months and maintained at 1 year. Macular threshold sensitivity improved 0.97 dB compared to placebo (P = 0.02), and percent reduced thresholds lessened 8.2% compared to the placebo arm (P = 0.04). The authors noted this was a pilot study and a larger study is planned.
- Study type
- Randomized, double-blind, placebo-controlled trial
- Who was studied
- 38 patients with early age-related macular degeneration
- What was measured
- Macular functions via micro-perimetry
THE PAPER
Evaluation of an oral telomerase activator for early age-related macular degeneration - a pilot study.
Dow CT, Harley CB. Clin Ophthalmol, 2016.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.